Congo begins trial of Gilead's ($GILD) experimental antiviral for Ebola Bundibugyo
Researchers in the Democratic Republic of Congo have started enrolling participants in a trial testing Gilead Sciences' experimental antiviral obeldesivir as a post-exposure treatment for the ongoing Bundibugyo Ebola outbreak in Congo and Uganda.